Paradigm Biopharmaceuticals (ASX:PAR) Sets New 12-Month High at $3.76
Paradigm Biopharmaceuticals Ltd (ASX:PAR)’s share price hit a new 52-week high during trading on Tuesday . The company traded as high as A$3.76 ($2.67) and last traded at A$3.75 ($2.66), with a volume of 1720268 shares traded. The stock had previously closed at A$3.36 ($2.38).
The stock has a market cap of $646.99 million and a P/E ratio of -34.40. The company has a current ratio of 30.51, a quick ratio of 30.46 and a debt-to-equity ratio of 0.04. The stock has a 50-day simple moving average of A$2.87.
About Paradigm Biopharmaceuticals (ASX:PAR)
Paradigm Biopharmaceuticals Limited, a biopharmaceutical company, engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulphate sodium drugs in the injectable and tablet forms for the treatment of bone marrow edema, respiratory, and alphaviral arthritis diseases.
See Also: What is a Candlestick Chart?
Receive News & Ratings for Paradigm Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paradigm Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.